9-(tetrahydro-2-furyl)-adenine and Leukemia--Promyelocytic--Acute

To explore the molecular mechanism of APL cell resistance to ATRA.. The ATRA sensitive and resistant APL cell lines, NB4 and NB4-R1, were used as in vitro models. The effects of specific inhibitors and activators of adenylate cyclase (AC) and phosphodiesterase (PDE) on ATRA-induced differentiation was evaluated by cell morphology, cell surface antigen expression and nitroblue-tetrazolium (NBT) reduction assays.. SQ22536, a specific antagonist of AC, could dramatically block ATRA-induced NB4 cell differentiation. When ATRA + SQ22536 group compared with ATRA group, the positivity of CD11b decreased from (95.9 +/- 2.5)% to (60.3 +/- 7.1)%, while the A(540) in NBT reduction assay decreased from 0.585 +/- 0.092 to 0.170 +/- 0.028 (P < 0.05). Forskolin, an agonist of AC, could overcome the resistance of NB4-R1 cells to ATRA. When ATRA + forskolin group compared with ATRA group, the positivity of CD11b increased from (34.3 +/- 5.3)% to (94.6 +/- 2.4)%, while the A(540) in NBT reduction assay increased from 0.110 +/- 0.028 to 0.395 +/- 0.049 (P < 0.05). In contrast, the specific antagonist and agonist of PDE, 3-isobutyl-1-methylxanthine (IBMX) and calmodulin, exerted little impact on ATRA treatment.. The defaults in the initiation of AC activation may contribute to the resistance to ATRA in some APL cells.

Topics: Adenine; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Antineoplastic Agents; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Phosphoric Diester Hydrolases; Tretinoin